The US Patent and Trademark Office published last week three patent applications related to RNA interference.

The first two — numbers 20030195138 and 20030194713 — are assigned to Rigel Pharmaceuticals and are directed to nucleic acids encoding the genes BAP-1 (BRCA1 associated protein-1) and NP95 (nuclear protein 95), respectively. Specifically, the patent applic- ations cover methods for identifying and using a number of agents, including RNAi-based ones, to regulate cell cycle arrest by modulation or BAP-1 or NP95.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.